NO975742D0 - Reversible cysteinproteasehemmere - Google Patents
Reversible cysteinproteasehemmereInfo
- Publication number
- NO975742D0 NO975742D0 NO975742A NO975742A NO975742D0 NO 975742 D0 NO975742 D0 NO 975742D0 NO 975742 A NO975742 A NO 975742A NO 975742 A NO975742 A NO 975742A NO 975742 D0 NO975742 D0 NO 975742D0
- Authority
- NO
- Norway
- Prior art keywords
- protease inhibitors
- cysteine protease
- reversible cysteine
- reversible
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47499395A | 1995-06-07 | 1995-06-07 | |
PCT/US1996/008559 WO1996040737A1 (en) | 1995-06-07 | 1996-06-03 | Reversible cysteine protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO975742D0 true NO975742D0 (no) | 1997-12-05 |
NO975742L NO975742L (no) | 1998-02-05 |
Family
ID=23885799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO975742A NO975742L (no) | 1995-06-07 | 1997-12-05 | Reversible cystein proteasehemmere |
Country Status (15)
Country | Link |
---|---|
US (1) | US6030946A (no) |
EP (1) | EP0832099A1 (no) |
JP (1) | JPH11507045A (no) |
KR (1) | KR19990022395A (no) |
CN (1) | CN1192219A (no) |
AR (1) | AR002328A1 (no) |
AU (1) | AU723658B2 (no) |
CA (1) | CA2222972A1 (no) |
CZ (1) | CZ390697A3 (no) |
NO (1) | NO975742L (no) |
NZ (1) | NZ309560A (no) |
PL (1) | PL323710A1 (no) |
TW (1) | TW438591B (no) |
WO (1) | WO1996040737A1 (no) |
ZA (1) | ZA964751B (no) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6586466B2 (en) | 1995-10-30 | 2003-07-01 | Smithkline Beecham Corporation | Carbohydrazide-protease inhibitors |
AP9801222A0 (en) * | 1995-10-30 | 1998-06-30 | Smithkline Beecham Corp | Proatease inhibitors. |
NZ324921A (en) | 1995-10-30 | 2000-07-28 | Smithkline Beecham Corp | Cathepsin K crystal structure and methods of identifying inhibitors of this protease |
CZ29799A3 (cs) * | 1996-07-30 | 1999-06-16 | Arris Pharmaceutical Corporation | Disubstituovaná cyklická sloučenina, způsob její výroby, farmaceutický přípravek a způsob léčení onemocnění živočicha |
US5830850A (en) * | 1996-08-28 | 1998-11-03 | Mount Sinai School Of Medicine Of The City Of New York | Methods for the treatment of bone resorption disorders, including osteoporosis |
FR2760193B1 (fr) * | 1997-02-28 | 1999-05-28 | Transgene Sa | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
DE69835430T2 (de) | 1997-05-30 | 2007-03-08 | Takeda Pharmaceutical Co. Ltd. | Sulfonamidderivate, ihre herstellung und verwendung |
AU2298899A (en) | 1998-02-05 | 1999-08-23 | Takeda Chemical Industries Ltd. | Sulfonamide derivatives, process for producing the same and utilization thereof |
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
US6294539B1 (en) * | 1999-01-19 | 2001-09-25 | Advanced Syntech, Llc | Heterocyclic hydroxamic acid derivatives as MMP inhibitors |
CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
ES2199856T3 (es) * | 1999-09-13 | 2004-03-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas. |
EP1232154A4 (en) | 1999-11-10 | 2004-06-23 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
EP1229914A4 (en) | 1999-11-10 | 2004-06-23 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
WO2001034599A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
AU4344101A (en) | 2000-03-21 | 2001-10-03 | Smithkline Beecham Corp | Protease inhibitors |
AU2001278084A1 (en) * | 2000-07-31 | 2002-02-13 | The Regents Of The University Of California | Model for alzheimer's disease and other neurodegenerative diseases |
US20050101587A9 (en) * | 2000-08-14 | 2005-05-12 | Butler Christopher R. | Method for treating allergies using substituted pyrazoles |
AU2001284823B2 (en) | 2000-08-14 | 2006-11-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
US20070105841A1 (en) * | 2000-08-14 | 2007-05-10 | Breitenbucher J G | Method for treating allergies using substituted pyrazoles |
US20070117785A1 (en) * | 2000-08-14 | 2007-05-24 | Butler Christopher R | Substituted pyrazoles and methods of treatment with substituted pyrazoles |
DE60126286T2 (de) * | 2000-08-14 | 2007-11-15 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte pyrazole |
EP1309593B1 (en) | 2000-08-14 | 2006-03-15 | Ortho-McNeil Pharmaceutical, Inc. | Substituted pyrazoles |
US7332494B2 (en) | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
AU2001288714A1 (en) * | 2000-09-06 | 2002-03-22 | Ortho-Mcneil Pharmaceutical, Inc. | A method for treating allergies |
WO2002036588A2 (en) * | 2000-11-06 | 2002-05-10 | U.S. Army Medical Research And Materiel Command | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
US6706754B2 (en) | 2000-11-06 | 2004-03-16 | The United States Of America As Represented By The Secretary Of The Army | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
HUP0303540A2 (hu) * | 2000-12-20 | 2004-01-28 | Bristol-Myers Squibb Pharma Co. | Diaminok mint kemokin receptor aktivitás modulátorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
WO2002060859A2 (en) * | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
JP2004520438A (ja) | 2001-03-09 | 2004-07-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | セリンプロテアーゼインヒビターとしてのアミノピロリジンスルホンアミド |
US6710061B2 (en) | 2001-03-09 | 2004-03-23 | Ortho-Mcneil Pharamceutical, Inc. | Aminopyrrolidine sulfonamides as serine protease inhibitors |
US6982263B2 (en) | 2001-06-08 | 2006-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitriles useful as reversible inhibitors of cysteine proteases |
US6780985B2 (en) | 2001-11-08 | 2004-08-24 | Ortho-Mcneil Pharmaceutical, Inc. | Polynucleotide and polypeptide sequences of Canine Cathepsin S |
US6784288B2 (en) | 2001-11-08 | 2004-08-31 | Ortho-Mcneil Pharmaceutical, Inc. | Polynucleotide and polypeptide sequences of monkey cathepsin S |
CA2467391A1 (en) * | 2001-11-14 | 2003-05-22 | Aventis Pharmaceuticals Inc. | Oligopeptides and compositions containing them as cathepsin s inhibitors |
DE10231574A1 (de) * | 2002-07-11 | 2004-01-29 | Sartorius Ag | Membran, Vorrichtung und Verfahren zum Entfernen von Proteasen aus Flüssigkeiten |
US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
US7384970B2 (en) * | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
US7173051B2 (en) * | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
US7256207B2 (en) * | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
US20060122266A1 (en) * | 2004-08-11 | 2006-06-08 | Photini Sinnis | Methods and compositions for malaria prophylaxis |
EP3434259A1 (en) | 2007-05-04 | 2019-01-30 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
AU2008350907A1 (en) * | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
EP2198879A1 (en) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell |
GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3859337A (en) * | 1969-06-11 | 1975-01-07 | Stauffer Chemical Co | Ethylenediaminetetraacetic acid anhydride derivatives |
IT1150959B (it) * | 1980-06-10 | 1986-12-17 | Simes | Sostanze datate di attivita' antispastica vasale e procedimenti per la loro preparazione |
JPH0832698B2 (ja) * | 1987-05-08 | 1996-03-29 | 日本ケミファ株式会社 | ピペラジン誘導体 |
WO1992008709A1 (de) * | 1990-11-15 | 1992-05-29 | Pentapharm Ag | Meta-substituierte phenylalanin-derivate |
AU1354292A (en) * | 1991-03-18 | 1992-10-21 | Pentapharm Ag | Parasubstituted phenylalanine derivates |
EP0635008B1 (de) * | 1993-02-10 | 2002-09-04 | Pentapharm A.G. | Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren |
-
1996
- 1996-06-01 TW TW085106569A patent/TW438591B/zh active
- 1996-06-03 CZ CZ973906A patent/CZ390697A3/cs unknown
- 1996-06-03 US US08/657,103 patent/US6030946A/en not_active Expired - Fee Related
- 1996-06-03 EP EP96917069A patent/EP0832099A1/en not_active Withdrawn
- 1996-06-03 CA CA002222972A patent/CA2222972A1/en not_active Abandoned
- 1996-06-03 NZ NZ309560A patent/NZ309560A/xx unknown
- 1996-06-03 AU AU59755/96A patent/AU723658B2/en not_active Ceased
- 1996-06-03 PL PL96323710A patent/PL323710A1/xx unknown
- 1996-06-03 CN CN96195858A patent/CN1192219A/zh active Pending
- 1996-06-03 WO PCT/US1996/008559 patent/WO1996040737A1/en not_active Application Discontinuation
- 1996-06-03 KR KR1019970708875A patent/KR19990022395A/ko not_active Application Discontinuation
- 1996-06-03 JP JP9501116A patent/JPH11507045A/ja active Pending
- 1996-06-05 AR ARP960102940A patent/AR002328A1/es unknown
- 1996-06-06 ZA ZA964751A patent/ZA964751B/xx unknown
-
1997
- 1997-12-05 NO NO975742A patent/NO975742L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU5975596A (en) | 1996-12-30 |
KR19990022395A (ko) | 1999-03-25 |
CA2222972A1 (en) | 1996-12-19 |
NZ309560A (en) | 1999-08-30 |
AU723658B2 (en) | 2000-08-31 |
US6030946A (en) | 2000-02-29 |
TW438591B (en) | 2001-06-07 |
CN1192219A (zh) | 1998-09-02 |
JPH11507045A (ja) | 1999-06-22 |
CZ390697A3 (cs) | 1998-04-15 |
PL323710A1 (en) | 1998-04-14 |
ZA964751B (en) | 1997-01-08 |
WO1996040737A1 (en) | 1996-12-19 |
NO975742L (no) | 1998-02-05 |
EP0832099A1 (en) | 1998-04-01 |
AR002328A1 (es) | 1998-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO975742D0 (no) | Reversible cysteinproteasehemmere | |
ATE259352T1 (de) | Cysteine protease inhibitoren | |
NO974403D0 (no) | Reversible proteasehemmere | |
NO20006717D0 (no) | Proteaseinhibitorer | |
NO995433D0 (no) | Protease-inhibitorer | |
NO20012980D0 (no) | Proteaseinhibitorer | |
ZA951573B (en) | Cysteine protease inhibitors | |
NO932620D0 (no) | Amindiol-proteaseinhibitorer | |
NO992492D0 (no) | Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer | |
EE9700266A (et) | Aspartüüli proteaasi THF-i sisaldavad sulfoonamiidinhibiitorid | |
ATE264339T1 (de) | Serine protease inhibitoren | |
NO973657D0 (no) | Trombin-inhibitorer | |
NO996578D0 (no) | Urokinase-inhibitorer | |
DK0858464T3 (da) | Thrombin-inhibitorer | |
NO995434L (no) | Proteaseinhibitorer | |
NO995435D0 (no) | Protease-inhibitorer | |
NO995268D0 (no) | Proteaseinhibitorer | |
EE9800044A (et) | Prolüülendopeptidaasi inhibiitorid | |
NO20011388D0 (no) | Hydroksamat-inneholdende cystein- og serinproteasehemmere | |
BR9610514A (pt) | Inibidores cicloantihelmínticos | |
BR9612344A (pt) | Inibidores de proteases | |
MA26429A1 (fr) | Inhibiteurs de protease | |
ZA969078B (en) | Inhibitors of cysteine protease. | |
KR970703937A (ko) | 금속단백질 분해효소 억제제(Metallproteinase inhibitors) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |